Latest Bayer AG News and Updates
Biogen’s Interferon Therapies Could Witness Modest Fall in 2017
In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.
Regeneron’s Dupixent Approved for Atopic Dermatitis
In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.
Must-know trends that drive Zoetis’ growth
Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.
Third Point believes Amgen’s acquisitions should have done more
Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.
Sanofi’s Organizational Restructuring: Investor Insights
On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.
How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017
In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.
How Pfizer’s Peri-LOE Products Performed in 2017
Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.
Pfizer’s Sutent Generated Higher Revenues in 4Q17
In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.
Analysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
How Biogen’s Biosimilars and Interferons Performed in 4Q17
In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17
In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.
How JNJ’s Consumer Products Performed in 3Q17
In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter.
How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver
After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.
How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
A Post-2Q17 Look at Pfizer’s Internal Medicines
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?
In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.
What We May See from Amgen’s Vectibix in 2017
Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
How Pfizer’s Internal Medicines Is Positioned in 2017
In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.
How Merck’s Animal Health Business Is Expected to Perform in 2017
In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.
Sector Composition of the Columbia European Equity Fund
The Columbia European Equity Fund Class A (AXEAX) invests in “equity securities of European companies that are believed to offer growth potential.”
Sector Composition Changes in AXEAX until 1Q16
AXEAX was invested across 69 holdings as of March 2016, seven more than a quarter ago. It was managing assets worth $515.6 million as of March.
How Are the USAA International Fund’s Metrics?
From a purely NAV (net asset value) return standpoint, the USIFX did not have a notable showing in either the one-year period until February 29, 2016, or in 2015.
ARTIX: How Is 2016 Looking so Far for the Fund?
The Artisan International Fund – Investor Class (ARTIX) has been in existence since December 1995.
How the Columbia European Equity Fund Fared until October
As of the September portfolio of the Columbia European Equity Fund, the top ten equity holdings included Novartis, Roche Holding, and Prudential Financial.
Essentials of the Artisan International Fund (ARTIX)
The Artisan International Fund (ARTIX) requires a minimum initial investment of $1,000. There’s no minimum or specific amount needed to add to an account.
The Columbia European Equity Fund Class A (AXEAX): Historical Overview
The Columbia European Equity Fund seeks capital appreciation by investing in “equity securities of European companies that…offer growth potential.”